Efficacy and Safety of Palbociclib in Heavily Pretreated Patients with HR+/HER2- Metastatic Breast Cancer

Abstract

Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.